Vosol

Infection, Communicable Diseases, Urinary Bladder + 2 more
Treatment
5 FDA approvals
6 Active Studies for Vosol

What is Vosol

Acetic acidThe Generic name of this drug
Treatment SummaryAcetic acid is a chemical found in ethanol and in wood that can be used to treat skin irritation or as a reagent. It can also be used in the form of an otic solution for the ear, which is an antibiotic used to treat bacterial or fungal infections.
Acetic Acidis the brand name
image of different drug pills on a surface
Vosol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Acetic Acid
Acetic acid
1979
33

Approved as Treatment by the FDA

Acetic acid, otherwise called Acetic Acid, is approved by the FDA for 5 uses which include External ear infection NOS and Urinary Bladder .
External ear infection NOS
Used to treat External ear infection NOS in combination with Acetic acid
Urinary Bladder
Urethral Catheters
Infection
Communicable Diseases
Used to treat External ear infection NOS in combination with Acetic acid

When to interrupt dosage

The measure of Vosol is dictated by the recognized disorder, including Bacterial infection, Urethral Catheters and Communicable Diseases. The amount additionally fluctuates as per the approach of delivery (e.g. Hemodialysis or Solution - Hemodialysis) outlined in the table beneath.
Condition
Dosage
Administration
Communicable Diseases
, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL
, Auricular (otic), Solution, Solution - Auricular (otic), Irrigation, Irrigant, Irrigant - Irrigation, Vaginal, Jelly, Jelly - Vaginal, Hemodialysis, Liquid, Liquid - Hemodialysis, Solution - Hemodialysis, Solution / drops, Solution / drops - Auricular (otic), Topical, Gel, Gel - Topical, Gel - Vaginal, Solution - Topical, Liquid - Topical
Infection
, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL
, Auricular (otic), Solution, Solution - Auricular (otic), Irrigation, Irrigant, Irrigant - Irrigation, Vaginal, Jelly, Jelly - Vaginal, Hemodialysis, Liquid, Liquid - Hemodialysis, Solution - Hemodialysis, Solution / drops, Solution / drops - Auricular (otic), Topical, Gel, Gel - Topical, Gel - Vaginal, Solution - Topical, Liquid - Topical
Urinary Bladder
, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL
, Auricular (otic), Solution, Solution - Auricular (otic), Irrigation, Irrigant, Irrigant - Irrigation, Vaginal, Jelly, Jelly - Vaginal, Hemodialysis, Liquid, Liquid - Hemodialysis, Solution - Hemodialysis, Solution / drops, Solution / drops - Auricular (otic), Topical, Gel, Gel - Topical, Gel - Vaginal, Solution - Topical, Liquid - Topical
Otitis Externa
, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL
, Auricular (otic), Solution, Solution - Auricular (otic), Irrigation, Irrigant, Irrigant - Irrigation, Vaginal, Jelly, Jelly - Vaginal, Hemodialysis, Liquid, Liquid - Hemodialysis, Solution - Hemodialysis, Solution / drops, Solution / drops - Auricular (otic), Topical, Gel, Gel - Topical, Gel - Vaginal, Solution - Topical, Liquid - Topical
Urethral Catheters
, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL
, Auricular (otic), Solution, Solution - Auricular (otic), Irrigation, Irrigant, Irrigant - Irrigation, Vaginal, Jelly, Jelly - Vaginal, Hemodialysis, Liquid, Liquid - Hemodialysis, Solution - Hemodialysis, Solution / drops, Solution / drops - Auricular (otic), Topical, Gel, Gel - Topical, Gel - Vaginal, Solution - Topical, Liquid - Topical

Warnings

Vosol has two impediments. If you have any of the conditions specified in the following table, Vosol should not be utilized.Vosol Contraindications
Condition
Risk Level
Notes
use during transurethral surgical procedures
Do Not Combine
Tympanic Membrane Perforation
Do Not Combine
There are 18 known major drug interactions with Vosol.
Common Vosol Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Acetic acid.
Typhoid vaccine
Minor
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Acetic acid.
(R)-warfarin
Moderate
The risk or severity of bleeding can be increased when Acetic acid is combined with (R)-warfarin.
(S)-Warfarin
Moderate
The risk or severity of bleeding can be increased when Acetic acid is combined with (S)-Warfarin.
4-hydroxycoumarin
Moderate
The risk or severity of bleeding can be increased when Acetic acid is combined with 4-hydroxycoumarin.
image of a doctor in a lab doing drug, clinical research

Vosol Novel Uses: Which Conditions Have a Clinical Trial Featuring Vosol?

16 active studies are currently exploring the potential of Vosol to combat Communicable Diseases, Infections and Urinary Bladder disorders.
Condition
Clinical Trials
Trial Phases
Urinary Bladder
0 Actively Recruiting
Otitis Externa
0 Actively Recruiting
Infection
6 Actively Recruiting
Not Applicable, Phase 1
Communicable Diseases
0 Actively Recruiting
Urethral Catheters
0 Actively Recruiting

Vosol Reviews: What are patients saying about Vosol?

5Patient Review
9/27/2009
Vosol for Outer Ear Inflammation caused by Allergy or Infection
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vosol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Vosol antibacterial?

"The clinical pharmacology of Vosol indicates that acetic acid is antibacterial and antifungal, while propylene glycol is hydrophilic and provides a low surface tension. Benzethonium chloride is a surface active agent that promotes contact of the solution with tissues."

Answered by AI

What is Vosol HC used for?

"This medication is a combination of two drugs, acetic acid and hydrocortisone, which are used to treat outer ear infections. Acetic acid kills bacteria and fungus, while hydrocortisone is a steroid that decreases the redness, swelling, and itching associated with the infection."

Answered by AI

What is Vosol?

"Vosol is an antibiotic that treats infections caused by bacteria or fungus. Vosol (for the ear) is used to treat infections in the ear canal. Vosol will not treat an inner ear infection (also called otitis media)."

Answered by AI

Is Vosol a prescription?

"If you experience a temporary stinging or burning sensation in your ear canal, tell your doctor or pharmacist. This medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects."

Answered by AI

Clinical Trials for Vosol

Image of National Institutes of Health Clinical Center in Bethesda, United States.

gp91 Grans for Chronic Granulomatous Disease

18 - 75
Male
Bethesda, MD
Background: CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells. Objective: To test a procedure in which mRNA is added to a person s blood cells. Eligibility: Males aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Swab to test for strep throat Some screening tests will be repeated during the study. Participants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days. After discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.
Phase 1
Recruiting
National Institutes of Health Clinical CenterSuk S De Ravin, M.D.
Image of University of Connecticut in Farmington, United States.

Prostate Biopsy Techniques for Reducing Infection Risk

18+
Male
Farmington, CT
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer. This randomized controlled trial will be the first prospective study to evaluate in-office transperineal MRI targeted prostate biopsy. The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer.
Recruiting
Has No Placebo
University of Connecticut (+16 Sites)Jim C Hu, MD MPH
Image of University of Iowa in Iowa City, United States.

Improved Perioperative Preventive Measures for Surgical Site Infections

18+
All Sexes
Iowa City, IA
Surgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capacity to acquire resistance and virulence traits. The investigators have proven that a multifaceted program involving improved basic perioperative preventive measures can generate substantial reductions in S. aureus transmission and significant reductions in SSIs (88% reduction as compared to usual care). In this study, the investigators aim to examine the relative effectiveness of each component of this program in controlling ESKAPE transmission and reducing SSIs and to identify an optimal implementation strategy for national dissemination. Randomization occurs at the site level, and sites adopt preventative programs. This work will improve perioperative patient safety for the 51 million patients who undergo surgery each year.
Recruiting
Has No Placebo
University of Iowa (+2 Sites)Jeremiah R Brown, PhD
Image of University of Ottawa Heart Institute in Ottawa, Canada.

Barrier Dressing for Infections

18+
All Sexes
Ottawa, Canada
This study will evaluate the effect of an iodine impregnated barrier dressing on device pocket swab culture positivity. Minimizing contamination during the implant procedure can be one of the potential improvements to prevent CIED infections. Patients requiring a lead change, battery change or device upgrade will be eligible. This is a randomized, blinded study where participants will be randomized to having the barrier dressing applied before any incision is made (experimental group) or applying the dressing just prior to collecting the culture swab (control group). Patients and the staff taking the culture swab at the end of the procedure are blinded as to which group the participant is randomized to.
Waitlist Available
Has No Placebo
University of Ottawa Heart InstituteAlper Aydin, Dr.
Have you considered Vosol clinical trials? We made a collection of clinical trials featuring Vosol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security